Literature DB >> 6332853

Lymphocyte changes during chronic administration of and withdrawal from corticosteroids: relation to Pneumocystis carinii pneumonia.

P D Walzer, M LaBine, T J Redington, M T Cushion.   

Abstract

Corticosteroids were administered for up to 8 wk in adult Lewis rats to provoke Pneumocystis carinii pneumonia, and lymphocyte subsets were analyzed at different body sites with monoclonal antibodies by flow microfluorometry in a fluorescence activated cell sorter. The rats became chronically ill, debilitated, and exhibited marked involution of all lymphoid tissues. The lymphocytopenia was characterized in peripheral blood by a large fall in the frequency of T helper cells, and in the lungs by a fall in T helper (Th) cells and a rise in T suppressor (Ts) cells; at both sites there was reversal of the Th to Ts ratio. These changes were not found in the thymus, spleen, or bone marrow. When corticosteroids were withdrawn, the rats gained weight, cleared P. carinii from the lungs, and regenerated their lymphoid tissues. The lymphocyte subpopulations exhibited variation in their frequencies at different body sites, but gradually returned to baseline levels. Thus, in this model chronic corticosteroid administration results in profound generalized lymphocyte depletion and changes in the proportions of circulating and pulmonary T cell subsets. These abnormalities may be an important immunologic mechanism in the development of P. carinii pneumonia.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6332853

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  20 in total

1.  Pharmacokinetic/pharmacodynamic modeling of total lymphocytes and selected subtypes after oral budesonide.

Authors:  Jeffrey G Stark; Sybille Werner; Susanne Homrighausen; Yufei Tang; Michael Krieg; Hartmut Derendorf; Helmut Moellmann; Guenther Hochhaus
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-04-22       Impact factor: 2.745

2.  The influence of prednisolone on the recirculation of peripheral blood lymphocytes in vivo.

Authors:  E Bloemena; S Weinreich; P T Schellekens
Journal:  Clin Exp Immunol       Date:  1990-06       Impact factor: 4.330

3.  The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung.

Authors:  A H Limper; J S Hoyte; J E Standing
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

4.  Time between inoculations and karyotype forms of Pneumocystis carinii f. sp. Carinii influence outcome of experimental coinfections in rats.

Authors:  M T Cushion; S Orr; S P Keely; J R Stringer
Journal:  Infect Immun       Date:  2001-01       Impact factor: 3.441

5.  Use of semiquantitative PCR to assess onset and treatment of Pneumocystis carinii infection in rat model.

Authors:  T J O'Leary; M M Tsai; C F Wright; M T Cushion
Journal:  J Clin Microbiol       Date:  1995-03       Impact factor: 5.948

6.  Pharmacokinetic/pharmacodynamic modeling of corticosterone suppression and lymphocytopenia by methylprednisolone in rats.

Authors:  Zhenling Yao; Debra C DuBois; Richard R Almon; William J Jusko
Journal:  J Pharm Sci       Date:  2008-07       Impact factor: 3.534

7.  Pneumocystis pneumonia in brain tumor patients: risk factors and clinical features.

Authors:  D Schiff
Journal:  J Neurooncol       Date:  1996-03       Impact factor: 4.130

8.  Proliferative and cytokine responses to a major surface glycoprotein of Pneumocystis carinii.

Authors:  S A Theus; M J Linke; R P Andrews; P D Walzer
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

9.  New rat model of Pneumocystis pneumonia induced by anti-CD4(+) T-lymphocyte antibodies.

Authors:  Timothy D Thullen; Alan D Ashbaugh; Kieran R Daly; Michael J Linke; Paul E Steele; Peter D Walzer
Journal:  Infect Immun       Date:  2003-11       Impact factor: 3.441

10.  Adoptive transfer of lymphocytes sensitized to the major surface glycoprotein of Pneumocystis carinii confers protection in the rat.

Authors:  S A Theus; R P Andrews; P Steele; P D Walzer
Journal:  J Clin Invest       Date:  1995-06       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.